Modulation of Extravascular Binding of Recombinant Factor IX Impacts the Duration of Efficacy in Mouse Models.
Journal
Thrombosis and haemostasis
ISSN: 2567-689X
Titre abrégé: Thromb Haemost
Pays: Germany
ID NLM: 7608063
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
medline:
26
7
2023
pubmed:
11
5
2023
entrez:
10
5
2023
Statut:
ppublish
Résumé
There is an emerging concept that in addition to circulating coagulation factor IX (FIX), extravascular FIX contributes to hemostasis. Our objective was to evaluate the efficacy of extravascular FIX using animal models of tail clip bleeding and ferric chloride-induced thrombosis. Mutant rFIX proteins with described enhanced (rFIX In vitro characterization demonstrated comparable clotting activity of rFIX proteins. The PK profile showed that rFIX Using two different
Sections du résumé
BACKGROUND
BACKGROUND
There is an emerging concept that in addition to circulating coagulation factor IX (FIX), extravascular FIX contributes to hemostasis.
OBJECTIVE
OBJECTIVE
Our objective was to evaluate the efficacy of extravascular FIX using animal models of tail clip bleeding and ferric chloride-induced thrombosis.
METHODS
METHODS
Mutant rFIX proteins with described enhanced (rFIX
RESULTS
RESULTS
In vitro characterization demonstrated comparable clotting activity of rFIX proteins. The PK profile showed that rFIX
CONCLUSION
CONCLUSIONS
Using two different
Identifiants
pubmed: 37164314
doi: 10.1055/a-2090-9739
pmc: PMC10365885
doi:
Substances chimiques
Factor IX
9001-28-9
ferric chloride
U38V3ZVV3V
Hemostatics
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
751-762Informations de copyright
The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Déclaration de conflit d'intérêts
All authors, except Michael Bacher are employees (and potentially shareholders) of CSL Behring Innovation GmbH.
Références
Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):11068-73
pubmed: 8855310
J Biol Chem. 1997 Jul 4;272(27):16717-20
pubmed: 9201971
J Biol Chem. 1992 Oct 15;267(29):20529-31
pubmed: 1400370
Blood. 2019 May 30;133(22):2445-2451
pubmed: 30992271
Biochem Biophys Res Commun. 1983 Mar 16;111(2):723-31
pubmed: 6404275
Haemophilia. 2020 May;26(3):e128-e129
pubmed: 32142196
JCI Insight. 2019 Jun 20;5:
pubmed: 31219805
J Phys Chem B. 2013 Oct 10;117(40):11906-20
pubmed: 24007457
J Biol Chem. 1981 Apr 10;256(7):3433-42
pubmed: 6782101
J Thromb Haemost. 2009 Nov;7(11):1843-51
pubmed: 19583826
Proc Natl Acad Sci U S A. 1983 Jul;80(13):4119-23
pubmed: 6602986
Blood. 2016 Jul 14;128(2):286-92
pubmed: 27106122
Thromb Haemost. 2001 Mar;85(3):560
pubmed: 11307831
Thromb J. 2016 Oct 4;14(Suppl 1):35
pubmed: 27766061
Br J Haematol. 1987 Jun;66(2):227-32
pubmed: 3496917
Haemophilia. 2020 Jan;26(1):e23-e25
pubmed: 31778004
Blood. 2002 Jul 1;100(1):153-8
pubmed: 12070021
Eur J Haematol. 2020 Jan;104(1):3-14
pubmed: 31606899
J Thromb Haemost. 2019 Jan;17(1):138-148
pubmed: 30418692